Market Data
Market Cap₹484.42 Cr.
52W High₹421
Current Price₹405.95
52W Low₹229.95
Down from 52W High3.6 %
Face Value₹10
Performance
ROCE19.45 %
ROE20.93 %
EPS (TTM)₹4.27
EPS Prev Qtr₹5.76
EPS Last Year₹4.27
EBITDA Qtr₹6.89 Cr.
Book Value₹84
Financial Health
Debt/Equity0.73
Debt/Profit3.38
Total Assets₹236.83 Cr.
Promoter Holding62.59 %
Earning Power10.65 %
Valuation
Stock P/E22.53
Industry P/E33.3
Price to Book4.82
Price to Sales3.44
Graham Number₹184.79
Key Metrics
Face Value
₹10
About Trident Lifeline Ltd
Healthcare · Pharmaceuticals
Trident Lifeline Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹484.42 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 31.34 | 25.71 | 49.95 | 33.72 |
| ↳ QoQ Growth | - | -18.0% | +94.3% | -32.5% |
| Expenses | 25.39 | 23.08 | 40.2 | 26.83 |
| Operating Profit | 5.95 | 2.63 | 9.75 | 6.89 |
| OPM % | 18.99% | 10.23% | 19.52% | 20.43% |
| Other Income | 1.67 | 4.63 | 1.62 | 0.57 |
| Interest | 0.99 | 1.24 | 0.77 | 0.86 |
| Depreciation | 0.91 | 2.46 | 1.23 | 1.62 |
| EBITDA | 6.86 | 5.09 | 10.98 | 8.51 |
| EBITDA Margin % | 21.89% | 19.8% | 21.98% | 25.24% |
| Profit Before Tax | 6.63 | 6.02 | 10.61 | 6.61 |
| Tax % | 23.23% | 22.76% | 35.91% | 23.3% |
| Net Profit | 5.09 | 4.65 | 6.8 | 5.07 |
| ↳ QoQ Growth | - | -8.6% | +46.2% | -25.4% |
| EPS | 4.27 | 3.72 | 5.76 | 4.27 |
Balance Sheet
| Mar 2023 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 11.5 | 11.4992 | 11.93 |
| Reserves | 34.14 | 52.9572 | 88.47 |
| Borrowings | 7.69 | 54.03 | 72.99 |
| Other Liabilities | 9.24 | 37.52 | 63.44 |
| Total Liabilities | 62.57 | 156.005 | 236.83 |
| Fixed Assets | 0.52 | 43.9178 | 42.58 |
| CWIP | 4.88 | 1.5622 | 17.5 |
| Investments | 3.34 | 10.72 | 8.27 |
| Other Assets | 53.83 | 99.81 | 168.48 |
| Total Assets | 62.57 | 156.005 | 236.83 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | -10.2417 |
| Cash from Investing Activity | -13.8247 |
| Cash from Financing Activity | 19.7605 |
| Net Cash Flow | -4.3059 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 63.11% | 64.11% | 62.85% | 62.59% |
| FIIs % | 7.71% | 7.04% | 7.24% | 5.25% |
| DIIs % | 0.41% | 0.35% | 0.27% | 0.26% |
| Public % | 17.63% | 17.29% | 18.67% | 20.58% |
| No. of Shareholders | 554 | 575 | 607 | 709 |